Kymera Therapeutics (KYMR)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Kymera Therapeutics (KYMR)
Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.
Key Insights
Critical company metrics and information
Share Price
$46.94Market Cap
$3.04 BillionTotal Outstanding Shares
64.77 Million SharesTotal Employees
184Dividend
No dividendIPO Date
August 21, 2020SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.kymeratx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Operating Activities, Continuing | $-124.67 Million |
Net Cash Flow | $29.66 Million |
Net Cash Flow From Investing Activities, Continuing | $-453.69 Million |
Net Cash Flow From Investing Activities | $-453.69 Million |
Net Cash Flow From Financing Activities, Continuing | $608.02 Million |
Net Cash Flow, Continuing | $29.66 Million |
Net Cash Flow From Operating Activities | $-124.67 Million |
Net Cash Flow From Financing Activities | $608.02 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Earnings Per Share | $2.34 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Operating Income/Loss | $-200.19 Million |
Income/Loss From Continuing Operations After Tax | $-167.47 Million |
Benefits Costs and Expenses | $188.81 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-167.47 Million |
Net Income/Loss | $-167.47 Million |
Revenues | $87.56 Million |
Diluted Earnings Per Share | $2.34 |
Income/Loss From Continuing Operations Before Tax | $-101.25 Million |
Other Operating Expenses | $66.35 Million |
Research and Development | $221.40 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Costs And Expenses | $264.67 Million |
Net Income/Loss Attributable To Parent | $-167.47 Million |
Basic Average Shares | $220.01 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Operating Expenses | $287.75 Million |
Diluted Average Shares | $220.01 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Current Liabilities | $66.53 Million |
Current Assets | $568.72 Million |
Assets | $1.03 Billion |
Liabilities And Equity | $1.03 Billion |
Other Non-current Assets | $414.88 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Equity Attributable To Parent | $892.93 Million |
Other Current Liabilities | $60.04 Million |
Noncurrent Assets | $466.13 Million |
Noncurrent Liabilities | $75.38 Million |
Fixed Assets | $51.24 Million |
Accounts Payable | $6.49 Million |
Equity | $892.93 Million |
Liabilities | $141.91 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.